These authors contributed equally to this work. + regulatory T cells (Tregs) are involved in graft-specific tolerance after solid organ transplantation. However, adoptive transfer of polyspecific Tregs alone is insufficient to prevent graft rejection even in rodent models, indicating that graft-specific Tregs are required. We developed a highly specific chimeric antigen receptor that recognizes the HLA molecule A*02 (referred to as A2-CAR). Transduction into natural regulatory T cells (nTregs) changes the specificity of the nTregs without alteration of their regulatory phenotype and epigenetic stability. Activation of nTregs via the A2-CAR induced proliferation and enhanced the suppressor function of modified nTregs. Compared with nTregs, A2-CAR Tregs exhibited superior control of strong allospecific immune responses in vitro and in humanized mouse models. A2-CAR Tregs completely prevented rejection of allogeneic target cells and tissues in immune reconstituted humanized mice in the absence of any immunosuppression. Therefore, these modified cells have great potential for incorporation into clinical trials of Treg-supported weaning after allogeneic transplantation.
Abbreviations: CAR, chimeric antigen receptor; CFSE, carboxyfluorescein diacetate succinimidyl ester; CTLA-4, cytotoxic T-lymphocyte-associated Protein 4; EGFP, enhanced green fluorescent protein; FACS, fluorescence-activated cell scanning; FFPE, Formalinfixed, paraffin-embedded; GFP, green fluorescent protein; H&E, hematoxylin and eosin; IL, intereukin; LNGFR, low-affinity nerve growth factor receptor; NFAT, nuclear factor of activated T cells; NRG, nonobese diabetic (NOD)-Rag1 null-
Introduction

FOXP3
+ regulatory T cells (Tregs) play an important role in donor hyporeactivity after solid organ transplantation (1) (2) (3) . While polyspecific Tregs can be used to prevent graft-versus-host disease in lymphopenic hosts after hematopoietic stem cell ablation (4), polyspecific Tregs are usually insufficient to prevent organ rejection in nonlymphopenic hosts after organ transplantation (5, 6) . This is most likely due to the high number of donor-reactive effector T cells (Teffs), which account for up to 12% of all peripheral T cells (7) . Thus, adoptive Treg therapy is reliant on the number of Tregs within the relevant alloimmune response niches (e.g. graft, draining lymph node, and perhaps spleen) (8) and on the reduction of alloreactive Teffs via depletion or immunosuppression (6) .
In addition to Treg numbers in lymphoid niches (9) , the importance of Treg specificity has been demonstrated (5, (10) (11) (12) (13) (14) (15) . While even large numbers of polyspecific Tregs were unable to control autoimmunity or alloreactivity, a single transfer of islet-or graft-specific Tregs established long-lasting immune tolerance in diabetes and allogeneic skin transplantation models. 
CD127
low nTregs (HLA-A*02-positive donor) showed no specificity for an HLA-A*0101-tetramer staining. All shown plots were representative of three independent experiments. CAR, chimeric antigen receptor.
Adoptive Treg therapy after solid organ transplantation might be a new option to induce tolerance and to minimize the side effects of chronic immunosuppression (16, 17) .
Because graft-specific Tregs exhibit much greater potency than do polyspecific Tregs (5, 6, 14, 18, 19) , the necessity to obtain large numbers of clinical-grade allospecific Tregs becomes apparent.
As an alternative strategy, we investigated the possibility of generating large numbers of donor-specific Tregs by changing the specificity of nTregs via transfer of chimeric antigen receptors (CARs) designed to recognize the MHC class allele A*02 in an peptide-independent manner (20, 21) .
Materials and Methods
Animals
Nonobese diabetic (NOD)-RAG1 null
IL2c
null (NRG) mice aged 8 to 10 weeks old were used. All mice were bred and kept under specific pathogen-free conditions in Hannover Medical School. All animal experiments were approved by the local Ethics Animal Review Board (Oldenburg, Germany, 11/0334) and performed in accordance with current German regulations.
Human subjects
Human specimens were obtained from different HLA-typed healthy donors. Local ethical committee approval was received for the studies. Informed consent of all participating subjects was obtained. ) were isolated via fluorescence-activated cell scanning (FACS) with the use of human peripheral blood mononuclear cells (PBMCs) with monoclonal antibody combinations: CD8 (HIT8a; BioLegend, San Diego, CA), CD4 (RPA-T4; BD), CD25 (M-A251; BD), and CD127 (hIL-7R-M21; BD). The FACS-based cell sorting was performed at the cell-sorting facility of Hannover Medical School and had a purity of >90%. Tregs were expanded by using Treg expansion beads (Miltenyi, Bergisch-Gladbach, Germany) according to the manufacturer's instructions.
Purification of human Tregs
Retrovirus production and cell transduction
Retroviral vector particles were generated as previously described (22) . Isolated CD4 + CD25 high CD127 low nTregs were stimulated with plate-bound aCD3 (OKT-3, self-made, 5 lg/mL) and soluble aCD28 (CD28.2; Biolegend, 5 lg/mL) in complete media for 48 h and then transduced. Before transduction, protamine sulfate (4 lg/mL; Sigma, Munich, Germany) was added to Treg cultures. Tregs were spin infected at 31°C for 1.5 h at 700 9 g with retroviral particles. CD4 + CD25 high CD127 low nTregs transduced with retroviral particles encoding the HLA-A*02 CARs were referred to as A2-CAR Tregs, and those transduced with particles encoding the control CARs were referred to as control CAR Tregs. The 48-h posttransduction positive transduced Tregs were isolated according to their low-affinity nerve growth factor receptor (LNGFR) surface expression with a purity of >90% and expanded with Treg expansion beads (see earlier).
Flow cytometry surface and intracellular staining of human Tregs
Experiments were usually performed after 7 to 10 days of rest in low (50 IU) interleukin (IL)-2. Antibodies used were DLNGFR (CD271, C40-1457; BD) and monoclonal antibody IgG-F(ab) (Jackson, West Grove, PA). low nTregs were isolated and divided into two fractions. One fraction was transduced with particles encoding A2-CAR. After transduction, positively transduced A2-CAR Tregs were isolated and expanded for 7 days. The nTreg fraction was cultured in parallel to A2-CAR Tregs. Except for the transduction, the two Treg products were cultured under the same conditions. DNA methylation analysis was performed through pyrosequencing as described previously (23) . Analyzed cells were paired from the same male donors.
Hybridoma coculture assay
The nuclear factor of activated T cells (NFAT)-green fluorescent protein (GFP) hybridoma cells (24) were transduced according to cell transduction protocol described earlier here with retroviral CAR construct. Various HLA-A*02-positive and -negative human PBMCs were used as stimulator cells. Coculture assays were performed for 20 h with CAR-transduced hybridoma cells and irradiated (30 Gy) stimulator cells in a 1:2 ratio. NFAT-driven GFP expression was analyzed by using FACS. 
Treg products and comparability
In vitro mixed lymphocyte reactions
Mixed lymphocyte reactions driven by allogeneic stimuli were performed as described previously (14) . 
In vivo mixed lymphocyte reaction
The in vivo mixed lymphocyte reaction was performed as previously described (13 HLA-A*02 PBMCs and injected into the ear pinnae of nonreconstituted NRG mice. Ear thickness was measured by using a spring-loaded digital thickness gauge before and 24 h after injection.
Reconstitution of NRG mice and in vivo killing
A total of 7.5 9 10 6 freshly isolated human HLA-A*02-negative PBMCs were injected intraperitoneally into NRG mice for immune reconstitution. The reconstitution was monitored by FACS 14 days postreconstitution.
We tested the killing of allogeneic target PBMCs in these immune reconstituted mice. To compensate for varying cell recovery from humanized mice, we gave a fixed 1:1 ratio of allogeneic targets and syngeneic control cells. ). Five days later, the animals were killed, blood specimens were collected, and spleens were removed from all animals and processed for FACS analysis.
Human skin transplant model
HLA-typed human skin allografts were transplanted onto the back of recipient NRG mice. After engraftment (referred as day 0), mice were injected intraperitoneally with 7.5 9 10
6 HLA-A*02-negative PBMCs with or without 1 9 10 6 A2-CAR Tregs. Mice were monitored every day for rejection signs.
Histology of human skin allografts
On the day of rejection/analysis, human skin grafts were formalin-fixed and embedded in paraffin. Formalin-fixed, paraffin-embedded (FFPE) sections (3 lm) were prepared for hematoxylin and eosin (H&E) staining. For immunofluorescence staining, FFPE sections were stained by using CD4 (clone EPR6855; Abcam, Cambridge, UK), FOXP3 (PCH101; eBioscience), and the appropriate fluorochrome-conjugated secondary antibody and the PE-conjugated ΔLNGFR (CD271, C40-1457; BD) (12) .
Statistical analysis
Statistical analyses were calculated with GraphPad Prism version 5.0. All statistical analyses and p-values are described in the figure legends.
Results
Generation of A2-CAR
Because the MHC class I molecule is constitutively expressed on the surface of all transplanted cells including passenger leukocytes emigrating from the graft after transplantation, we hypothesized that the MHC class I molecule would be an appropriate target for a CAR. Seventy percent of white transplant recipients are HLA-A*02 negative and 30% of organ donors are HLA-A*02 positive (25), so an A2-CAR could potentially be used for 21% of all transplantations. To obtain high-affinity HLA-A*02-specific single-chain variable fragments (scFvs), we used scFvs generated from a phage display library from a patient who was allosensitized by an HLA-A*02-positive blood transfusion leading to posttransfusion purpura 5 days after the transfusion. (26) . The scFvs were cloned into a newly generated second-generation CAR backbone consisting of a human CD8 hinge and transmembrane region fused to the intracellular CD28 and CD3 f -ITAM motifs for intracellular signaling (Figures 1A and B) (27) . The A2-CAR construct was cloned into a d-retroviral LTR-driven RSF91 expression vector. For control experiments, we cloned a control CAR construct recognizing PE into the same backbone. To monitor CAR-transduced Tregs, DLNGFR, a nonsignaling, nonimmunogenic surface molecule, was expressed from an internal ribosomal entry site. This marker can also be used for magnetic isolation of transduced cells under Good Manufacturing Practices conditions.
Surface expression of our CAR constructs was confirmed by costaining for IgG and DLNGFR after transduction of hybridoma cells (transduction efficiency usually between 90% and 99%) ( Figure 1C ). Transduction efficiency of nTregs was usually between 55% and 95% (in very rare cases, it was <10%: Figure 3 ). We initially tested the specificity of the A2-CAR by staining with MHC I tetramers. While transduced cells were stained with an A*02-tetramer displaying a hepatitis C virus peptide ( Figure 1D ), no staining was observed with an A*01-tetramer ( Figure 1E ). The staining was independent of the peptide bound to the A*02-tetramer (data not shown). The control CAR was specific for PE as shown by staining with various PE-containing reagents (Figure S1 ).
Characteristics of A2-CAR-transduced Tregs
The A2-CAR construct was then used to transduce sorted CD4 + CD25 high CD127 low nTregs from HLA-A*02-negative individuals to prevent activation after transduction with the A2-CAR and to approximate the situation in the transplant setting. The transduction protocol did not affect the nTreg phenotype. nTregs, A2-CAR, and control CAR-transduced Tregs displayed similar levels of effector molecules CTLA-4 and CD39, similar percentages of CD45RA + na€ ıve Tregs, and similar expressions of CCR7 needed for homing to secondary lymphoid organs (Figures 2A and B) , as well as comparable levels of FOXP3 expression ( Figure 2C ). Because the stability of the nTreg phenotype will be major importance when using antigenspecific Tregs, we also analyzed the epigenetic modifications at the Treg-specific demethylated region (TSDR), the current gold standard for stable nTregs (28) . Compared with nTregs, A2-CAR Tregs preserved a stable demethylation pattern at all sites in the TSDR after transduction with the A2-CAR suggesting a stable nTreg low Tregs from HLA-A*02-negative donors were transduced with A2-CAR or with the control CAR and compared with nTregs for expression of CCR7, CD39, CD45RO/RA, and cytotoxic T-lymphocyteassociated protein 4 (CTLA-4). Representative histograms were shown. (B) Bars represent summary of all performed three independent experiments. Data are shown as mean AESD (unpaired, two-tailed Student's t-test). (C) Summary of FACS analysis for FOXP3 expression in expanded nTregs, A2-CAR, and control CAR Tregs after isolation, transduction, and expansion. Data are shown as mean AESD (unpaired, two-tailed Student's t-test). (D) Genomic DNA of A2-CAR Tregs and nTregs from male human subjects were isolated and subjected to pyrosequencing to determine TSDR demethylation status of isolated A2-CAR Tregs as well as nTregs. Amplicons are subdivided by horizontal lines, each representing an individual CpG motif. The methylation status of individual CpG motifs is color coded according to the degree of methylation at that site. The color code ranges from yellow (0% methylation) to blue (100% methylation) according to the color scale. Results represent one of three independent experiments. CAR, chimeric antigen receptor; FACS, fluorescence-activated cell scanning; Treg, regulatory T cell. phenotype ( Figure 2D ). As functionally insufficient human nTregs were reported to exhibit diminished IL-2 signal transduction with reduced STAT5 phosphorylation (29), we compared STAT5 phosphorylation in A2-CARtransduced nTregs and non-transduced nTregs from the same experiment. Both Treg populations showed high levels of STAT5 phosphorylation already under the low doses of IL-2 necessary for nTreg survival in culture ( Figures 3A and B) . Therefore, no defects in IL-2 signaling were observed.
Functional characteristics of A2-CAR-transduced Tregs
To more closely analyze the functional specificity of the A2-CAR, we transduced T cell hybridomas stably expressing a reporter construct with an NFAT-sensitive IL-2 promoter, which drives GFP expression. While A2-CAR-transduced hybridomas did not show any NFAT activation or the associated GFP expression after transduction, NFAT activation was strongly upregulated after coculture with HLA-A*02-positive PBMCs as stimulator cells ( Figures 4A and B, Figure S2 ). In contrast, no such activation was observed with hybridomas transduced with the control CAR. This demonstrated that our second-generation CAR construct was capable of strong signal transduction necessary to activate NFAT. Moreover, as the hybridomas do not express any endogenous T cell receptors (TCRs), the observed signal transduction was entirely due to A2-CAR signaling. The differentiation between CAR and TCR signaling will be more difficult when HLA-A*02-negative donor nTregs are transduced with the A2-CAR, because 8-12% of these nTregs will have a TCR that recognize allogeneic targets; including HLA-A*02. We subsequently tested the A2-CAR against a wide panel of human PBMCs with various MHC class I and II alleles. Our flow cytometric analyses of GFP expression demonstrated that the A2-CAR-transduced hybridomas recognized all HLA-A*02-positive donor samples without any cross-reactivity with HLA-A*02-negative blood specimens (Table 1, Figure S2 ). In contrast, comparable experiments with hybridoma cells transduced with a control CAR resulted in no GFP expression after coculture with either HLA-A*01-or HLA-A*02-positive PBMCs. This demonstrated the high specificity of our A2-CAR construct, which should translate into low offtarget effects.
We then studied the functional consequences of activating human HLA-A*02-negative nTregs via the A2-CAR after transduction. Activation via the A2-CAR led to a strong proliferation and upregulation of the CD39 effector molecule. This effect was much stronger in A2-CAR Tregs than in control CAR Tregs (Figures 4C-E) . The CD39 upregulation was also observed on activation via the TCR with aCD3/aCD28. These data indicate that A2-CAR-transduced Tregs can be activated equally well via the CAR or via the TCR. The high proliferative capacity of A2-CAR-transduced nTregs should enhance their nichefilling capabilities after transfer into patients.
To investigate if the signaling via the A2-CAR also enhances the suppressive properties of the nTregs, we tested the capabilities of A2-CAR-transduced CD4 + CD25 + CD127 low nTregs to suppress an allogeneic mixed lymphocyte reaction directed against HLA-A*02-positive stimulator cells in coculture assays. The A2-CARtransduced nTregs inhibited allospecific Teff proliferation stronger than that of nonspecific CD4 + CD25 high Tregs (Figures 4F and G) . In fact, the A2-CAR Tregs were more potent at almost all Treg:Teff ratios tested. Inhibition of >60% was still observed at a 1:64 Treg:Teff ratio, demonstrating the strong suppressive capacity of A2-CAR Tregs ( Figure 4F ). Further, A2-CAR Tregs showed significant higher suppressive capacity than control CAR Tregs in dilutions >1:32 Treg:Teffs ratios ( Figure 4G ).
Functional properties of A2-CAR nTregs in humanized mice
The demonstration of efficacy and safety of adoptive Treg transfer in humanized mouse models has already paved the way for clinical translation into studies like "The ONE Trial." Therefore, we tested the efficacy of A2-CAR Tregs to inhibit alloimmune responses in humanized NRG mice. On testing the capabilities of various nTregs to inhibit a delayed-type hypersensitivity caused by a strong allogeneic mixed lymphocyte reaction, the A2-CAR Tregs suppressed the ear swelling response significantly stronger than did the CD4 + CD25 high nTregs and Tregs transduced with the control CAR ( Figure 5A ). In fact, the A2-CAR Tregs almost completely inhibited the allospecific immune reaction, while CD4 + CD25 high nTregs inhibited only 40% of the response.
We next tested the suppressive properties of A2-CAR Tregs in immune reconstituted humanized NRG mice. Initially, we used a stringent rejection model in which allogeneic target cells (HLA-A*02-positive PBMCS labeled with CFSE) were completely rejected by day 5 after transfer ( Figure 5B ). By colabeling syngeneic and allogeneic target cells, it was possible to assess the relative killing because both cell populations were given at a 1:1 ratio. In this setting, allogeneic targets were no longer detected by day 5 after transfer, mimicking the fast rejection of allogeneic targets in immunocompetent mice (Figures 5C and D) . While adoptive transfer of polyspecific nTregs and nTregs transduced with a control CAR had only a small effect in preventing the killing of allogeneic targets, transfer of A2-CAR Tregs completely prevented the rejection of allogeneic targets ( Figures 5C and D) . Finally, we also tested the ability of A2-CAR Tregs to prevent the rejection of allogeneic tissues in immune reconstituted humanized mice. Immune reconstituted mice without Treg transfer completely rejected their grafts by day 37. The addition of polyspecific nTregs led to a small, yet nonsignificant, prolongation of graft survival but was unable to induce tolerance. In contrast, the transfer of A2-CAR Tregs completely prevented the rejection of HLA-A*02-positive human skin grafts until day 40 without the need of immunosuppression ( Figure 5E ). At that time, the experiments had to be stopped because the animals developed a xenogeneic graft-versus-host reaction. However, all skin grafts were still viable without any signs of rejection ( Figure 6A ).
When we analyzed the skin grafts via histologic examination, an immune infiltrate was visible even in tolerated grafts of mice receiving A2-CAR Tregs ( Figure 6B ). However, costaining for CD4 and FOXP3 revealed that 30% of infiltrating CD4 + T cells were FOXP3 + after the transfer of A2-CAR Tregs. This number tended to be higher than that in mice receiving nTregs and no Tregs ( Figure 6C ). In fact, FOXP3-expressing A2-CAR Tregs were also DLNGFR positive, showing long-term persistence of transferred A2-CAR Tregs within the graft ( Figure 6D ). 
Discussion
We describe a new, potentially therapeutically useful strategy to generate large amounts of graft-specific Tregs by changing the specificity of nTregs via transduction with an HLA-A*02-specific CAR. This procedure can be performed with limited in vitro culture time, allowing the stable phenotype of nTregs and their epigenetic landscape to be retained. Moreover, the population of CD45RA-na€ ıve Tregs was preserved in A2-CAR Treg cultures, as well as the capacity to home to secondary lymphoid organs as shown by expression of CCR7. Importantly, A2-CAR Tregs exhibited greater proliferative capacity than did nTregs or Tregs transduced with a control CAR.
A2-CAR Tregs are also more potent than nTregs in inhibiting an in vitro allogeneic mixed lymphocyte reaction. Most important, A2-CAR Tregs were far more potent in suppressing an allogeneic DTH immune response in humanized mice compared with CD4 + CD25 high nTregs. When we tested the A2-CAR Tregs in immune reconstituted humanized mice, they could completely prevent the killing of allogeneic HLA-A*02-positive human target cells and HLA-A*02-positive human skin grafts. The Japanese group of Todo et al has recently provided first evidence that Treg-enriched cell transfer could be used for successful Treg-supported weaning early after liver transplantation (17) , so A2-CAR Tregs could have a therapeutic potential.
While CAR-transduced T cells have recently been successfully used to eliminate CD19 + lymphoma cells (30,31), a major obstacle facing cancer immunology is that many tumor entities do not have specific identified surface molecules to be targeted by CARs. In contrast, in the transplantation setting, neoantigens of the donor offer an excellent target and are constitutively expressed 
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-responder T cells. Data are shown as mean AESD (unpaired, two-tailed Student's t-test, *p = 0.01). CAR, chimeric antigen receptor; CFSE, carboxyfluorescein diacetate succinimidyl ester; NFAT, nuclear factor of activated T cells; PBMC, peripheral blood mononuclear cell; Teff, effector T cell; Treg, regulatory T cell. Recently, self-activation by tonic CAR signaling through antigen-independent clustering of scFv domains was reported (32) . Such antigen-independent signaling is unlikely to occur with our A2-CAR, as we detected no NFAT signaling or proliferation in the absence of antigen.
It remains to be determined if prolonged in vitro expansion affects the stability of the Treg phenotype, the Treg purity, and the subsequent in vivo survival after adoptive transfer (33), as was reported for Teffs after prolonged in vitro expansion. It was shown that the TCR repertoire of in vitro expanded Tregs changes dramatically during expansion (34) . In most current trials, Tregs for adoptive transfer were already harvested before transplantation, which can be problematic in severely ill patients awaiting liver, lung, or heart transplantation. In contrast, A2-CAR Tregs can be generated as an "off-the-shelf" therapeutic strategy with limited in vitro expansion time, as has been shown in recent trials using CAR-modified T cells in cancer immunology. Moreover, it should be feasible to perform transduction of nTregs obtained posttransplantation. As the stability of the Treg phenotype has recently been questioned in chronically inflamed tissue (35) (36) (37) (39) . However, this is the first time that a potentially clinically meaningful and highly specific CAR was generated for Treg modification. The strong effects in immune reconstituted humanized mice might warrant further testing for clinical trials. CARs specific for transplanted neoantigens might unravel the real potential of the CAR technology as the targets are expressed only on the target tissues.
Levings and coworkers recently published similar results using a different HLA-A*0201-specific CAR (40) . Most of their findings support our data. The parallel and independent scientific work underscores the unmet need of generating donor-specific cell Treg therapies. However, there are also some subtle differences: As specificity is of major importance to avoid off-target toxicity, we have tested our A2-CAR against a wide variety of non-HLA-A*0201 donors in an experimental setting, where the activation signal was generated just by the CAR. We intentionally avoided performing specificity assays in the presence of alloreactive TCRs (like in HLA-A*02 positive nTregs). For the same reason, we also used the hybridoma system to test the ability for signal transduction all the way down to activation of an NFAT-dependent promotor. Finally, we put a strong emphasis on characterizing the in vivo effects of A2-CAR Tregs in clinical meaningful settings in three humanized mouse models. A2-CAR Tregs were superior to nTregs in preventing an allospecific delayed-type 4 Treg products to an allogeneic PBMC mixture. Statistical analysis was calculated by one-way ANOVA. (E) Adoptive transfer of A2-CAR Tregs preserved HLA-A*02 human skin grafts in HLA-A*01 reconstituted humanized mice. Human HLA-A*02 skin was transplanted on the back of NRG mice. After engraftment (referred as day 0), animals were subdivided into three groups. All groups were reconstituted with 7.5 9 10 6 allogeneic HLA-A*01 PBMCS. One group received contemporaneous 1 9 10 6 adoptively transferred A2-CAR Tregs (syngeneic to HLA-A*01 PBMCs used for reconstitution), one group received contemporaneous 1 9 10 6 adoptively transferred nTregs (syngeneic to HLA-A*01 PBMCs used for reconstitution), and one group received no additional nTregs. Graph summarizes graft survival of transplanted human skin on animals received A2-CAR Tregs (n = 7; light gray line), received nTregs (n = 5, dark gray line) and on control animals with no cell therapeutic intervention (n = 6; black line). Animals from the A2-CAR group were taken out of the experiment on days 22, 30, 36, 37, 38, and 40 ( ) due to death with functioning graft (DWF) with xenogeneic graft-versus-host disease (log-rank [Mantel-Cox] test, ***p = 0.001, **p = 0.002, ns: p = 0.17). CAR, chimeric antigen receptor; CFSE, carboxyfluorescein diacetate succinimidyl ester; FACS, fluorescence-activated cell scanning; NFAT, nuclear factor of activated T cells; PBMC, peripheral blood mononuclear cell; Teff, effector T cell; Treg, regulatory T cell. This means that all recipient cells are MHC A*02, so that A2-CAR Tregs will be broadly activated and thereby cause a systemic immunosuppression. Moreover, mice receiving A2-CAR failed to reconstitute their immune system, which could also contribute to the lack of rejection.
Taken together, A2-CAR Tregs might thereby offer the possibility to induce graft-specific tolerance. These modified Tregs are readily available through a short transduction protocol without the need of prolonged in vitro expansion. Due to the high specificity of transplanted neoantigens, off-target effects are expected to be minimal. Because Treg-supported weaning was recently shown to be clinically applicable (17) , A2-CAR Tregs might offer a novel strategy to achieve tolerance after organ transplantation. Figure 6 : Protection of allogeneic HLA-A*02-positive skin grafts from alloimmune injury by A2-CAR Tregs. Human HLA-A*02 skin was transplanted on the back of NRG mice. After engraftment, animals were subdivided in three groups. All groups were reconstituted with 7.5 9 10 6 allogeneic HLA-A*02-negative PBMCs. One group received contemporaneous 1 9 10 6 adoptively transferred A2-CAR Tregs (syngeneic to HLA-A*02-negative PBMCs used for reconstitution), one group received contemporaneous 1 9 10 
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